Deborah L Buffington

US Patent:

6913588, Jul 5, 2005

Filed:

Mar 28, 2003

Appl. No.:

10/402912

Inventors:

William Frederick Weitzel - Ypsilanti MI, US
H. David Humes - Ann Arbor MI, US
Emil Presley Paganini - Chesterland OH, US
Deborah Ann Buffington - Ann Arbor MI, US
Angela J. Funke - Ann Arbor MI, US

Assignee:

Nephros Therapeutics, Inc. - Lincoln RI
The Regents of the University of Michigan - Ann Arbor MI

International Classification:

A61M037/00
C02F001/44

US Classification:

604 609, 604 401, 604 501, 604 504, 604 606, 604 611, 210645, 210646

Abstract:

A circuit for extracorporeal treatment of a body fluid, the circuit including in serial fluidic communication an inlet for receiving the body fluid from a patient, a first pump, a first treatment device for processing the body fluid, a second pump, an outlet for returning processed body fluid to the patient; and a shunt. The shunt is upstream from the first pump and downstream from the second pump.

US Patent:

7332330, Feb 19, 2008

Filed:

Sep 11, 2001

Appl. No.:

09/949575

Inventors:

H. David Humes - Ann Arbor MI, US
William H. Fissell - Whitmore Lake MI, US
Deborah A. Buffington - Ann Arbor MI, US
Evangelos Tziampazis - Plymouth MI, US

Assignee:

RenaMed Biologics, Inc. - Lincoln RI

International Classification:

C12M 3/06
A61F 2/00
C12N 5/02
C12N 11/04

US Classification:

4352971, 424423, 435182, 4352831

Abstract:

A device and a method of maintaining vascularization near an implant, especially a bioartificial hemofilter. By associating cells that excrete angiogenic factors with such an implant, vascularization to the tissue surrounding the implant can be maintained. In a bioartificial hemofilter, this facilitates filtrate transport to a collection fiber for drainage from the body. The cells can be genetically engineered, for example using an adenovirus vector encoding for vascular endothelial growth factor. Myoblasts and myotubes may be used in one embodiment of the present invention.

US Patent:

8251941, Aug 28, 2012

Filed:

Aug 29, 2008

Appl. No.:

12/201576

Inventors:

H. David Humes - Ann Arbor MI, US
Deborah Buffington - Ann Arbor MI, US

Assignee:

The Regents of the University of Michigan - Ann Arbor MI
CytoPherx, Inc. - Ann Arbor MI

International Classification:

A61M 37/00
C02F 1/44

US Classification:

604 603, 604 601, 604 607, 604 609, 210645

Abstract:

The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.

US Patent:

8409126, Apr 2, 2013

Filed:

Jun 30, 2010

Appl. No.:

12/827606

Inventors:

H. David Humes - Ann Arbor MI, US
Deborah Buffington - Ann Arbor MI, US

Assignee:

The Regents of the University of Michigan - Ann Arbor MI
CytoPherx, Inc. - Ann Arbor MI

International Classification:

A61M 37/00
C02F 1/44

US Classification:

604 603, 604 601, 604 607, 604 609, 210645

Abstract:

The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.

US Patent:

8425445, Apr 23, 2013

Filed:

Jun 30, 2010

Appl. No.:

12/827594

Inventors:

H. David Humes - Ann Arbor MI, US
Deborah Buffington - Ann Arbor MI, US

Assignee:

The Regents of the University of Michigan - Ann Arbor MI
CytoPherx, Inc. - Ann Arbor MI

International Classification:

A61M 37/00

US Classification:

604 603, 604 401, 604 501, 604 601, 604 609

Abstract:

The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.

US Patent:

8425446, Apr 23, 2013

Filed:

Jun 30, 2010

Appl. No.:

12/827609

Inventors:

H. David Humes - Ann Arbor MI, US
Deborah Buffington - Ann Arbor MI, US

Assignee:

The Regents of the University of Michigan - Ann Arbor MI
CytoPherx, Inc. - Ann Arbor MI

International Classification:

A61M 37/00

US Classification:

604 603, 604 401, 604 501, 604 601, 604 609

Abstract:

The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.

US Patent:

8425447, Apr 23, 2013

Filed:

Aug 23, 2012

Appl. No.:

13/593169

Inventors:

H. David Humes - Ann Arbor MI, US
Deborah Buffington - Ann Arbor MI, US

Assignee:

The Regents of the University of Michigan - Ann Arbor MI
CytoPherx, Inc. - Ann Arbor MI

International Classification:

A61M 37/00

US Classification:

604 603, 604 401, 604 501, 604 601, 604 609

Abstract:

The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.

US Patent:

8430832, Apr 30, 2013

Filed:

Jun 30, 2010

Appl. No.:

12/827601

Inventors:

H. David Humes - Ann Arbor MI, US
Deborah Buffington - Ann Arbor MI, US

Assignee:

The Regents of the University of Michigan - Ann Arbor MI
CytoPherx, Inc. - Ann Arbor MI

International Classification:

A61M 37/00

US Classification:

604 603, 604 401, 604 501, 604 601, 604 609

Abstract:

The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.